SEARLE

Research in the service of mankind

SEPTEMBER 2025
QUARTERLY REPORT

Elevating life by advancing health
& well-being for generations to come

Contents

Company Information

Board of Directors

Mr. Adnan Asdar Ali	Non-Executive Director	Chairman
Mr. Tahir Ahmed	Executive Director	Chief Executive Officer
Mr. Munis Abdullah	Non-Executive Director	
Mr. S. Nadeem Ahmed	Executive Director	
Mr. Zubair Razzak Palwala	Non-Executive Director	
Ms. Shaista Khaliq Rehman	Independent Director	
Mr. Muhammed Zubair Haider Shaikh	Independent Director	

Board of Audit Committee

Ms. Shaista Khaliq Rehman	Chairperson
Mr. Adnan Asdar Ali	Member
Mr. Munis Abdullah	Member

Board of HR & Remuneration Committee

Mr. Muhammad Zubair Haider Shaikh	Chairman
Mr. Munis Abdullah	Member
Ms. Shaista Khaliq Rehman	Member

Chief Financial Officer

Mr. S. Asim Raza Zaidi

Company Secretary

Mr. Mudassir Habib Khan

Auditors

A. F. Ferguson & Co.

Legal Advisors

Mohsin Tayebaly & Co.

Bankers

Al Baraka Bank (Pakistan) Limited
Askari Bank Limited
Bank AL Habib Limited
Bank Alfalah Limited
The Bank of Punjab
Dubai Islamic Bank Pakistan Limited
Faysal Bank Limited
Habib Bank Limited
Habib Metropolitan Bank Limited
Meezan Bank Limited
National Bank of Pakistan
Soneri Bank Limited

SHARE REGISTRAR

CDS Share Registrar Services Limited
Head Office, CDC House,
99-B, Block 'B' S.M.C.H.S.,
Main Shahrah-e-Faisal
Karachi - 74400

REGISTERED OFFICE

One IBL Centre, 2nd Floor, Plot #
1, Block 7 & 8 D.M.C.H.S.,
Tipu Sultan Road,
Off Shahra-e-Faisal Karachi

Directors' Report to the Members

We are pleased to present the unconsolidated interim financial information of the company for the three months ended September 30, 2025. These financial statements have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 – 'Interim Financial Reporting'. The directors' report is prepared in accordance with section 227 of the Companies Act, 2017 and Chapter XII of the Listed Companies (Code of Corporate Governance) Regulations, 2019.

Financial highlights

The company reported revenue of Rs. 8.57 billion, reflecting a 28% increase compared to the same period last year. The significant growth in sales was underpinned by enhanced operational efficiencies, particularly through optimization of supply chain processes and effective allocation of financial resources. The gross profit margin improved to 55.9%, marking a 10.1 percentage point increase year-on-year. This improvement was primarily driven by strategic price adjustments and a favorable shift in the product mix.

Finance costs declined substantially to Rs. 279 million, down from Rs. 741 million in the corresponding period last year. This reduction was largely attributable to lower interest rates and the settlement of long-term borrowings following the divestment of SPL.

As a result, the company recorded a profit after tax of Rs. 854 million, compared to Rs. 301 million in the corresponding quarter of the previous year.

Below is a summary of the financial results for the three months ended September 30, 2025:

	Quarter ended	
	September 30, 2025	September 30, 2024
	(Rupees in thousand)	
Revenue from contracts with customers	8,567,319	6,677,620
Cost of sales	(3,777,796)	(3,616,743)
Gross Profit	**4,789,523**	**3,060,877**
Distribution costs	(2,614,501)	(1,528,881)
Administrative expenses	(414,016)	(339,967)
Other expenses	(118,882)	(38,118)
Other income	36,123	36,111
Profit from operations	**1,678,247**	**1,190,022**
Finance cost	(279,035)	(741,189)
Profit before levies and income tax	**1,399,212**	**448,833**
Levies – minimum tax and final tax	(11,547)	(13,531)
Profit before income tax	**1,387,665**	**435,302**
Income tax credit / (expense)	(534,145)	(134,521)
Profit for the period	**853,520**	**300,781**

EARNINGS PER SHARE

Basic earnings per share after taxation for the period is Rs. 1.67 (September 2024: Rs. 0.59). There is no dilution effect on the basic earnings per share of the Company, as the Company had no convertible dilutive potential ordinary shares outstanding as at September 30, 2025.

FUTURE OUTLOOK

Searle remains focused on expanding its market presence and sustaining organic growth while continuing to improve lives. Despite ongoing macroeconomic and geopolitical challenges, the Company is confident in its ability to navigate these with resilience and deliver consistent performance.

Recent developments, including the deregulation of non-essential drug prices, lower interest rates, and a stable exchange rate have improved business predictability and created a favorable environment for growth. The recent approval of Denosumab injections by the Drug Regulatory Authority of Pakistan marks another milestone in Searle's biosimilar journey, strengthening its leadership in biotechnology and access to affordable advanced therapies.

The Company continues to build momentum in exports, particularly across GCC and CIS markets, supported by new manufacturing approvals from regional health authorities. At the same time, Searle is accelerating its digital transformation and sustainability initiatives to enhance operational efficiency and align with global standards.

We thank our shareholders for their continued trust and support. Searle remains committed to disciplined execution, innovation, and creating enduring value for all stakeholders.

For and on behalf of the Board

Tahir Ahmed
Chief Executive Officer

Zubair Palwala
Director

Karachi: October 24, 2025

فی حصص آمدنی

اس مدت کے لیے ٹیکس کے بعد فی شیئر بنیادی آمدنی 1.67 روپے ہے (30 ستمبر 2024 : (0.59) روپے)۔ کمپنی کی فی حصص بنیادی آمدنی پر کسی قسم کی کمی کا اثر نہیں ہوا، کیونکہ 30 ستمبر 2025 تک کمپنی کے پاس کوئی قابل تبدیل ممکنہ منفی اثر ڈالنے والے عام حصص موجود نہیں تھے۔

مستقبل کا جائزہ

سرل (Searle) کی توجہ سماجی، اقتصادی، سیاسی، اور ماحولیاتی چیلنجوں کو نبرد آزما ہوتے ہوئے، نامیاتی طور پر اور اسٹریٹجک حصول کے ذریعے ترقی پر مرکوز ہے۔ ہمارا فعال نقطہ نظر اور بروقت فیصلہ سازی کا عزم ہمیں بیرونی غیر یقینی صورتحال جیسے کہ شرح مبادلہ کے اتار چڑھاو، افراط زر کے دباؤ اور بڑھتی ہوئی عالمی قیمتوں سے نمٹنے کے لیے اچھی پوزیشن میں رکھتا ہے۔

ADALIMUMAB ، پاکستان کی پہلی مقامی طور پر تیار کی جانے والی بایو سیملر دوا کی منظوری کے ساتھ ، ہم اپنی بائیو ٹیکنالوجی پیشکشوں کو مضبوط کرنے کے لیے تیار ہیں۔ مزید برآں، غیر ضروری ادویات کی قیمتوں کی حالیہ ڈی ریگولیشن اور گرتی ہوئی سود کی شرح ہمارے کاروبار کے منصوبوں میں مدد کرتے ہوئے منافع میں اضافہ کرے گی۔

ہم اہم بین الاقوامی منڈیوں میں برآمدی محصولات میں اضافہ کرنے کے منصوبوں کے ساتھ اپنے پروڈکٹ پورٹ فولیو کو متنوع بنانے، علاج کے نئے شعبوں کی تلاش، اور جغرافیائی طور پر توسیع کرنا جاری رکھے ہوئے ہیں۔ سرل (Searle) جدت اور باہمی تعاون کے ذریعے ہمارے اسٹیک ہولڈرز کے لیے طویل مدتی، پائیدار ترقی اور قدر پیدا کرنے کے لیے اچھی پوزیشن میں ہے۔

بورڈ کے لیے اور اس کی جانب سے

Ahmed

طاہر احمد
چیف ایگزیکٹو آفیسر

Zubair Palwala

زبیر رزاق پال والا
ڈائریکٹر

کراچی: 24 اکتوبر 2025

ڈائریکٹرز رپورٹ برائے حصص یافتگان

ہمیں خوشی ہے کہ ہم کمپنی کی 30 ستمبر 2025 کو ختم ہونے والی سہ ماہی کے غیر متفقہ شدہ عبوری مالیاتی گوشوارے پیش کر رہے ہیں۔ یہ مالیاتی گوشوارے بین الاقوامی اکاؤنٹنگ اسٹینڈرڈ ''34 (IAS)–عبوری مالیاتی رپورٹنگ'' کے تقاضوں کے مطابق تیار کیے گئے ہیں۔ ڈائریکٹرز کی یہ رپورٹ کمپنیز ایکٹ 2017 کی دفعہ 227 اور لسٹڈ کمپنیز (کارپوریٹ گورننس کے ضابطہ اخلاق) ریگولیشنز 2019 کے باب XII کے تحت تیار کی گئی ہے۔

مالی جھلکیاں

کمپنی نے 8.57 ارب روپے کی آمدنی رپورٹ کی، جو گزشتہ سال کے اسی عرصے کے مقابلے میں 28%اضافہ ظاہر کرتی ہے۔ فروخت میں نمایاں اضافہ بہتر عملی کارکردگی بالخصوص سپلائی چین کے عمل کو بہتر بنانے اور مالی وسائل کے مؤثر استعمال، کے باعث ہوا ہے ۔ مجموعی منافع کا مارجن 55.9% تک بہتر ہوا، جو سال بہ سال 10.1 فیصد پوائنٹس کا اضافہ ظاہر کرتا ہے۔ یہ بہتری بنیادی طور پر اسٹریٹجک قیمتوں میں ایڈجسٹمنٹ اور مصنوعات کے مجموعے (Product Mix) میں سازگار تبدیلی کے نتیجے میں ہوئی۔

مالیاتی اخراجات نمایاں طور پر کم ہو کر 279 ملین روپے رہ گئے، جو گزشتہ سال کے اسی عرصے میں 741 ملین روپے تھے۔ یہ کمی بنیادی طور پر کم شرحِ سود اور ایس پی ایل (SPL) کے اثاثوں کی فروخت کے بعد طویل مدتی قرضوں کی ادائیگی کی وجہ سے ہوئی۔

نتیجتاً، کمپنی نے بعد از ٹیکس 854 ملین روپے کا منافع ریکارڈ کیا، جو گزشتہ سال کی اسی سہ ماہی میں 301 ملین روپے تھا۔

ذیل میں 30 ستمبر 2025 کو ختم ہونے والے تین ماہ کے مالیاتی نتائج کا خلاصہ پیش کیا جا رہا ہے:

	اختتام پذیر سہ ماہی	
	30 ستمبر 2025	30 ستمبر 2024
	(پاکستانی روپے ہزاروں میں)	
گاہکوں کے ساتھ معاہدوں سے حاصل ہونے والی آمدنی	8,567,319	6,677,620
فروخت کی لاگت	(3,777,796)	(3,616,743)
مجموعی منافع	**4,789,523**	**3,060,877**
ترسیل کے اخراجات	(2,614,501)	(1,528,881)
انتظامی اخراجات	(414,016)	(339,967)
دیگر اخراجات	(118,882)	(38,118)
دیگر آمدنی	36,123	36,111
آپریشنز سے منافع/نقصان	**1,678,247**	**1,190,022**
مالیاتی لاگت	(279,035)	(741,189)
لیویز اور انکم ٹیکس سے قبل منافع	**1,399,212**	**448,833**
لیویز - کم از کم ٹیکس اور حتمی ٹیکس	(11,547)	(13,531)
منافع قبل از ٹیکس	**1,387,665**	**435,302**
انکم ٹیکس کے اخراجات	**(534,145)**	**(134,521)**
منافع بعد از ٹیکس	**853,520**	**300,781**

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION

As at September 30, 2025

	Note	(Un-audited) September 30 2025	(Audited) June 30 2025
		(Rupees in '000)	
ASSETS			
Non-current assets			
Property, plant and equipment	6	**7,577,145**	7,632,409
Right-of-use asset		**38,215**	40,770
Investment properties - at cost		**2,899,239**	2,923,493
Intangible assets		**9,075**	12,131
Deferred tax assets		**1,242,706**	1,214,703
Long-term investments - subsidiaries		**9,666,718**	9,666,718
Long-term loans		**46**	61
Long-term deposits		**7,396**	7,396
		21,440,540	21,497,681
Current assets			
Stock-in-trade		**3,874,318**	3,717,103
Trade receivables	7	**10,419,346**	9,487,605
Loans and advances	8	**2,236,994**	2,027,914
Trade deposits and short-term prepayments		**272,000**	204,026
Other receivables	9	**5,089,343**	5,261,130
Short-term investment - at amortised cost		**-**	100,000
Taxation - payments less provision		**1,508,069**	1,985,688
Tax refunds due from Government - sales Tax		**184,026**	254,262
Cash and bank balances		**151,273**	140,211
		23,735,369	23,177,939
Total assets		**45,175,909**	**44,675,620**
EQUITY AND LIABILITIES			
EQUITY			
Share Capital			
Issued, subscribed and paid-up capital		**5,114,945**	5,114,945
Capital Reserves			
Share premium		**9,085,133**	9,085,133
Revaluation surplus on property, plant and equipment		**4,521,720**	4,582,517
Revenue reserves			
General reserve		**280,251**	280,251
Unappropriated profit		**12,091,154**	11,176,837
Total equity		**31,093,203**	30,239,683
LIABILITIES			
Non-current liabilities			
Employee benefit obligations		**57,788**	58,380
Long-term borrowings	10	**42,791**	46,067
Lease liabilities		**54,789**	57,514
		155,368	161,961
Current liabilities			
Trade and other payables	11	**6,292,266**	6,102,229
Short-term borrowings	12	**7,370,894**	7,910,150
Contract liabilities		**33,735**	31,030
Unpaid dividend		**182,340**	182,340
Unclaimed dividend		**36,703**	36,827
Current portion of lease liabilities		**11,400**	11,400
		13,927,338	14,273,976
Total liabilities		**14,082,706**	14,435,937
Contingencies and commitments	13		
Total equity and liabilities		**45,175,909**	44,675,620

The annexed notes from 1 to 22 form an integral part of these condensed interim financial statements.

Chief Executive | Director | Chief Financial Officer

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the period ended September 30, 2025 - Unaudited

		Quarter ended	
		September 30 2025	September 30 2024
		(Rupees in '000)	
	Note		
Revenue from contracts with customers	14	**8,567,319**	6,677,620
Cost of sales		**(3,777,796)**	(3,616,743)
Gross profit		**4,789,523**	3,060,877
Distribution costs		**(2,614,501)**	(1,528,881)
Administrative expenses		**(414,016)**	(339,967)
Other expenses		**(118,882)**	(38,118)
Other income	15	**36,123**	36,111
Profit from operations		**1,678,247**	1,190,022
Finance cost		**(279,035)**	(741,189)
Profit before levies and income tax		**1,399,212**	448,833
Levies - minimum tax and final tax		**(11,547)**	(13,531)
Profit before income tax		**1,387,665**	435,302
Income tax credit / (expense)		**(534,145)**	(134,521)
Profit for the period		**853,520**	300,781
Other comprehensive income		**-**	-
Total comprehensive income		**853,520**	300,781
			(Re-stated)
Earnings per share - basic and diluted	16	**1.67**	0.59

The annexed notes from 1 to 22 form an integral part of these condensed interim financial statements.

Chief Executive

Director

Chief Financial Officer

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY

For the period ended September 30, 2025 - Unaudited

			Capital reserve		Revenue reserves			
	Issued, subscribed and paid-up capital	Advance received against issue of share capital	Share premium	Revaluation surplus on Property, plant & equipment	General reserve	Unappro-priated profits	Total reserves	Total
	----------Rupees '000----------							
Balance as at July 01, 2024	5,114,945	-	9,085,133	4,062,375	280,251	10,552,225	23,979,984	29,094,929
Transfer of incremental depreciation for the period (net of deferred tax)	-	-	-	(50,261)	-	50,261	-	-
Total comprehensive income for the period	-	-	-	-	-	300,781	300,781	300,781
Balance as at September 30, 2024	5,114,945	-	9,085,133	4,012,114	280,251	10,903,267	24,280,765	29,395,710
Balance as at July 01, 2025	**5,114,945**	**-**	**9,085,133**	**4,582,517**	**280,251**	**11,176,837**	**25,124,738**	**30,239,683**
Transfer of incremental depreciation for the period (net of deferred tax)	-	-	-	**(60,797)**	-	**60,797**	**-**	**-**
Total comprehensive income for the period	**-**	**-**	**-**	**-**	**-**	**853,520**	**853,520**	**853,520**
Balance as at September 30, 2025	**5,114,945**	**-**	**9,085,133**	**4,521,720**	**280,251**	**12,091,154**	**25,978,258**	**31,093,203**

The annexed notes from 1 to 22 form an integral part of these condensed interim financial statements.

Chief Executive | Director | Chief Financial Officer

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF CASH FLOWS

For the period ended September 30, 2025 - Unaudited

	Note	September 30 2025	September 30 2024
		(Rupees in '000)	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	17	**756,406**	825,874
Employees benefit obligations paid		**(1,942)**	-
Finance cost paid		**(255,666)**	(494,882)
Income taxes paid		**(96,076)**	(56,442)
Long-term loans		**15**	28
Net cash generated from operating activities		**402,737**	274,578
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		**(91,203)**	(67,767)
Proceeds from disposal of property, plant and equipment		**45**	-
Addition to investment properties		**(454)**	(5,060)
Proceeds from disposal of subsidiary		**150,000**	-
Proceeds from short-term investments		**100,000**	-
Net cash used in investing activities		**158,390**	(72,827)
CASH FLOWS FROM FINANCING ACTIVITIES			
Dividend paid		**(124)**	(192)
Repayment of short term finance facility		**(300,000)**	-
Repayment of long-term borrowings		**(3,276)**	(524,609)
(Repayment)/proceeds from running musharaka		**(105,609)**	328,299
Payment against lease liabilities		**(7,409)**	(9,503)
Net cash from financing activities		**(416,418)**	(206,005)
Net increase in cash and cash equivalents		**144,709**	(4,254)
Cash and cash equivalents at the beginning of the period		**(1,154,995)**	(1,172,715)
Cash and cash equivalents at the end of the period	18	**(1,010,286)**	(1,176,969)

The annexed notes from 1 to 22 form an integral part of these condensed interim financial statements.

Chief Executive | Director | Chief Financial Officer

1. THE COMPANY AND ITS OPERATIONS

1.1 The Searle Company Limited (the Company) was incorporated in Pakistan as a private limited company in October 1965. In November 1993, the Company was converted into a public limited company under the repealed Companies Ordinance, 1984 (now the Companies Act, 2017). Its shares are quoted on the Pakistan Stock Exchange Limited (PSX). The Company is principally engaged in the manufacture of pharmaceutical and other consumer products.

International Brands (Private) Limited is the Parent Company, which holds 50.25% (June 2025: 50.25%) shareholding in the Company.

1.2 Following are the subsidiary companies:

	Principal place of business	Effective %age of holding	
		September 30 2025	June 30 2025
Listed Company			
- IBL HealthCare Limited	Pakistan	**74.19%**	74.19%
Unlisted Companies			
- Searle Pharmaceuticals (Private) Limited	Pakistan	**100.00%**	100.00%
- Searle Laboratories (Private) Limited	Pakistan	**100.00%**	100.00%
- Searle Biosciences (Private) Limited	Pakistan	**100.00%**	100.00%
- IBL Future Technologies (Private) Limited	Pakistan	**100.00%**	100.00%
- Nextar Pharma (Private) Limited *	Pakistan	**87.20%**	87.20%
- Searle IV Solutions (Private) Limited	Pakistan	**100.00%**	100.00%
- Stellar Ventures (Private) Limited	Pakistan	**100.00%**	100.00%
- Mycart (Private) Limited *	Pakistan	**50.00%**	50.00%
- IBL Frontier Markets (Private) Limited *	Pakistan	**100.00%**	100.00%
- Prime Health (Private) Limited *	Pakistan	**100.00%**	100.00%

* *Nextar Pharma (Private) Limited is the subsidiary of Searle Biosciences (Private) Limited being the indirect subsidiary of the Company.*

* *Mycart (Private) Limited, IBL Frontier Markets (Private) Limited and Prime Health (Private) Limited are the subsidiaries of Stellar Ventures (Private) Limited being the indirect subsidiaries of the Company.*

1.3 These unconsolidated condensed interim financial statements are separate financial statements of the Company in which investments in subsidiaries have been accounted for at cost less accumulated impairment losses, if any.

2. BASIS OF PREPARATION

2.1 Statement of compliance

2.1.1 These unconsolidated condensed interim financial statements of the Company have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprises of:

- International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and

- Islamic Financial Accounting Standards (IFAS) issued by the Institute of Chartered Accountants of Pakistan as notified under the Companies Act, 2017; and

- Provisions of and directives issued under the Companies Act, 2017

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

2.1.2 These unconsolidated condensed interim financial statements does not include all the information required for full financial statements and should be read in conjunction with the audited annual unconsolidated financial statements of the Company as at and for the year ended June 30, 2025.

2.1.3 The comparative unconsolidated condensed interim statement of financial position presented in these unconsolidated condensed interim financial statements have been extracted from the audited annual unconsolidated financial statements of the Company for the year ended June 30, 2025, whereas the comparative unconsolidated condensed interim statement of profit or loss and other comprehensive income, unconsolidated condensed interim statement of cash flows and unconsolidated condensed interim statement of changes in equity are extracted from the un-audited unconsolidated condensed interim financial statements for the period ended September 30, 2024.

2.2 Basis of measurement

These condensed interim unconsolidated financial statements have been prepared under the historical cost convention except as stated otherwise and should be read in conjunction with the audited annual unconsolidated financial statements of the Company as at and for the year ended June 30, 2025.

2.3 Functional and presentation currency

These condensed interim financial statements are presented in Pakistani Rupees which is also the Company's functional currency. All financial information presented in Pakistani Rupees has been rounded off to the nearest thousand Rupee except where stated otherwise.

3. MATERIAL ACCOUNTING POLICY INFORMATION

3.1 The accounting policies and methods of computation adopted in the preparation of these unconsolidated condensed interim financial statements are the same as those applied in the preparation of the audited annual unconsolidated financial statements of the Company as at and for the year ended June 30, 2025.

3.2 Changes in accounting standards, interpretations and pronouncements

a) Standards and amendments to approved accounting standards that are effective

There are certain standards, amendments and interpretations to the accounting and reporting standards which are mandatory for the Company's annual accounting period which began on July 1, 2025. However, these do not have any significant impact on the Company's financial reporting.

b) Standards and amendments to approved accounting standards that are not yet effective

There are standards, certain amendments and interpretations to the accounting and reporting standards that will be mandatory for the Company's annual accounting periods beginning on or after July 1, 2026. However, these are considered either not to be relevant or to have any significant impact on the Company's unconsolidated financial standards and operations and, therefore, have not been disclosed in these unconsolidated financial statements.

4. FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES

The carrying values of all financial assets and liabilities reflected in these unconsolidated condensed interim financial statements approximate to their fair value.

5. ACCOUNTING ESTIMATES AND JUDGEMENTS AND FINANCIAL RISK MANAGEMENT

5.1 The preparation of the unconsolidated condensed interim financial statements in conformity with accounting and reporting standards, as applicable in Pakistan, requires management to make judgements, estimates and assumptions that affect the application of the accounting policies and the reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

5.2 The significant judgements made by the management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the audited annual unconsolidated financial statements as at and for the year ended June 30, 2025.

5.3 The Company's financial risk management objectives and policies are consistent with those disclosed in the audited annual unconsolidated financial statements for the year ended June 30, 2025.

		(Unaudited) September 30 2025	(Audited) June 30, 2025
6.	**PROPERTY, PLANT AND EQUIPMENT**	(Rupees in '000)	
	Operating assets - note 6.1	**7,105,502**	7,232,877
	Capital work-in-progress - at cost	**471,643**	399,532
		7,577,145	7,632,409

6.1 Details of additions in operating assets including transfers from capital work-in-progress during the period are as follows:

	Additions (at cost)		Disposals (at net book value)	
	Sept. 30, 2025	Sept. 30, 2024	**Sept. 30, 2025**	Sept. 30, 2024
	(Rupees in '000)			
Building on leasehold land	**2,658**	8,087	**-**	-
Plant and machinery	**230**	7,803	**-**	-
Furniture & fittings	**552**	-	**-**	-
Office equipment	**15,654**	19,324	**(262)**	-
	19,094	35,214	**(262)**	-

		(Unaudited) September 30 2025	(Audited) June 30, 2025
7	**TRADE RECEIVABLES**	(Rupees in '000)	
	Considered good		
	- Due from related parties, unsecured	**8,288,100**	7,390,351
	- Export receivables - secured	**928,152**	844,040
	- others - unsecured	**1,401,651**	1,451,771
		10,617,903	9,686,162
	Less: allowance for expected credit losses	**(198,557)**	(198,557)
		10,419,346	9,487,605

8 LOANS AND ADVANCES

8.1 These include advances to Searle Biosciences (Private) Limited amounting to Rs. 826.39 million (June 30, 2025: Rs. 786.39 million), Searle IV Solutions (Private) Limited amounting to Rs. 357.82 million (June 30, 2025: Rs. 499.35 million), and Stellar Ventures (Private) Limited amounting to Rs. 234.34 million (June 30, 2025: Rs. 205.19 million), wholly owned subsidiaries. These are provided for the purpose of financial assistance and are settled in the ordinary course of business.

	(Unaudited) September 30 2025	(Audited) June 30, 2025
9 OTHER RECEIVABLES	(Rupees in '000)	
Receivables from related parties		
Due from subsidiary companies:		
IBL Healthcare Limited against:		
Expenses	**804**	-
Royalty	**54,587**	54,587
Rental income	**1,240**	-
Searle Biosciences (Private) Limited against:		
Facility Management Fee	**220,000**	220,000
Expenses	**171,052**	171,052
Searle IV Solutions (Private) Limited against Expenses	**60,097**	60,097
IBL Frontier Markets (Private) Limited against expenses	**50,623**	52,873
Nextar Pharma (Private) Limited against expenses	**-**	3,680
	558,403	562,289
Due from parent company		
International Brands (Private) Limited against:		
Expenses	**125,588**	213,798
Rental income	**29,591**	24,133
Group relief	**58,040**	58,040
	213,219	295,971
Due from associated companies		
IBL Operations (Private) Limited against:		
Expenses	**8,954**	8,857
Rental income	**10,445**	6,619
IBL Unisys (Private) Limited against:		
Rental income	**-**	776
Expenses	**-**	1,116
Universal Ventures (Private) Limited against:		
Sale of subsidiary	**86,452**	86,452
Due from other related party:		
United Retail (SMC-Private) Limited against:		
Rental income	**9,151**	7,400
Expenses	**81,976**	67,786
Universal Retail (Private) Limited against:		
Rental income	**50,301**	35,624
Expenses	**152,013**	140,631
	399,292	355,261
Surplus arising under retirement benefit fund	**5,250**	5,250
Receivables from other than related parties		
Noventa Pharma (Private) Limited against:		
Sale of subsidiary	**3,400,917**	3,550,917
Others, considered good	**512,262**	491,442
	5,089,343	5,261,130

		(Unaudited) September 30 2025	(Audited) June 30, 2025
10.	**LONG-TERM BORROWINGS**	(Rupees in '000)	
	Diminishing Musharika	**57,094**	60,370
	Less: Current portion of long-term loans	**(14,303)**	(14,303)
		42,791	46,067

10.1. This represents sale and leaseback transaction entered by the Company with First Habib Modarabah Limited for two generators and a lift. At the end of lease term, the assets will be transferred back to the Company, hence it does not constitute a sale under IFRS 15.

10.2. These facilities are secured by way of:

Registered hypothecation charge over specific Plant & Machinery equivalent to the value of asset purchased under Diminishing Musharakah.

Post dated cheques of all the remaining installments under the financing scheme.

Registration of the said Vehicle under the name of the First Habib Modarabah Limited.

		(Unaudited) September 30 2025	(Audited) June 30, 2025
11.	**TRADE AND OTHER PAYABLES**	(Rupees in '000)	
	Creditors	**888,224**	1,354,475
	Bills payable in foreign currency	**1,195,854**	1,414,453
	Payable to related parties	**117,003**	415,164
	Royalty payable	**59,187**	59,187
	Accrued liabilities	**2,440,394**	1,345,680
	Payable to provident fund	**23,827**	135,227
	Accrued mark-up	**228,895**	219,605
	Taxes deducted at source and payable to statutory authorities	**1,004,113**	928,417
	Workers' Profit Participation Fund	**126,994**	51,089
	Workers' Welfare Fund	**100,926**	72,083
	Other liabilities	**106,849**	106,849
		6,292,266	6,102,229

		(Unaudited) September 30 2025	(Audited) June 30, 2025
12.	**SHORT-TERM BORROWINGS**	(Rupees in '000)	
	Secured borrowings		
	Conventional		
	Running finance facility - note -12.1	**1,161,559**	1,295,206
	Short-term finance facility	**-**	300,000
		1,161,559	1,595,206
	Islamic		
	Running Musharaka	**5,995,032**	6,100,641
	Current portion of long-term borrowings - note -12.1.1	**14,303**	14,303
		6,009,335	6,114,944
		7,170,894	7,710,150
	Unsecured		
	Borrowing from IBL Future Technologies (Private) Limited - note 12.2	**200,000**	200,000
		7,370,894	7,910,150

12.1 The Company has entered into running finance under mark-up arrangements from various banks amounting to Rs. 7,650 million (June 30, 2025: Rs. 7,650 million) which include financing facilities obtained under Islamic mode amounting to Rs. 6350 million (June 30, 2025: Rs. 6,350 million). The arrangements are secured jointly by registered mortgage of Rs. 1937.5 million (June 30, 2025: Rs. 1,937.5 million) of immovable property together with joint pari passu charge on all current assets of the Company to the extent of Rs. 11,095.83 million (June 30, 2025: Rs. 11,095.83 million).

12.1.1 The rates of mark-up ranged between 11.64% to 13.64% (June 30, 2025: 12.33% to 22.96%) per annum.

12.2 This represents interest free loan obtained from IBL Future Technologies (Private) Limited - wholly owned subsidiary and is repayable on demand.

13. CONTINGENCIES AND COMMITMENTS

13.1 Contingencies

There has been no significant change in the status of contingencies as reported in the note 30 of annual audited financial statements of the Company for the year ended June 30, 2025.

13.2 Commitments

		(Unaudited) September 30 2025	(Audited) June 30, 2025
		(Rupees in '000)	
13.2.1	Commitments in respect of capital expenditures		
	Property, plant and equipment	**2,754**	6,766

13.2.2 Post-dated cheques issued in favour of Collector of Customs for import of inventory at September 30, 2025 amounted to Rs. 206.95 million (June 30, 2025: Rs. 197.65 million).

13.2.3 The facility for opening letters of credit and guarantees as at September 30, 2025 amounted to Rs. 2,982 million (June 30, 2025: Rs. 3,265 million) of which the amount remaining unutilised as at year end amounted to Rs. 1,981 million (June 30, 2025: Rs. 1,180 million).

	September 30 2025	September 30 2024
	(Rupees in '000)	
14. REVENUE FROM CONTRACTS WITH CUSTOMERS		
Gross sales		
Local sale of goods	**8,588,311**	7,193,365
Export sales	**851,775**	787,418
	9,440,086	7,980,783
Toll manufacturing	**1,245**	-
	9,441,331	7,980,783
Sales tax	**(113,461)**	(61,458)
	9,327,870	7,919,325
Less:		
Trade discount	**(440,074)**	(491,930)
Sales return	**(320,477)**	(749,775)
	(760,551)	(1,241,705)
	8,567,319	6,677,620
15. OTHER INCOME		
Income from financial assets - others		
Interest Income from Term Finance Certificates	**-**	5,505
Income from non - financial assets		
Rental income from investment property	**25,681**	22,490
Gain on disposal of property, plant and equipment	**45**	-
Scrap sales	**8,497**	8,116
Others	**1,900**	-
	36,123	30,606
	36,123	36,111

16.	**BASIC AND DILUTED EARNINGS PER SHARE**	**September 30 2025**	September 30 2024
	Profit for the period (Rupees in thousands)	**853,520**	300,781
	Weighted average number of outstanding shares at the end of period (in thousand) - Restated	**511,494**	511,494
			(Re-stated)
	Basic and diluted earnings per share (Rupees)	**1.67**	0.59

17.	**CASH GENERATED FROM OPERATIONS**	**September 30 2025**	September 30 2024
		(Rupees in '000)	
	Profit before levies and income tax	**1,399,212**	448,833
	Add adjustments for non-cash charges and other items		
	Depreciation	**173,468**	156,159
	Gain on disposal of property, plant and equipment	**217**	-
	Amortisation of intangible assets	**3,054**	3,556
	Amortisation of transaction cost	**-**	4,212
	Provision for retirement benefits obligation	**1,350**	1,350
	Finance cost	**264,956**	734,615
	Interest on lease liability	**4,684**	6,573
	Profit before working capital changes	**1,846,941**	1,355,298
	Effect on cash flow due to working capital changes		
	(Increase) / decrease in current assets		
	Inventories	**(157,215)**	(32,425)
	Trade receivables	**(931,741)**	332,069
	Loans and advances	**(209,080)**	14,554
	Trade deposits and short-term prepayments	**(67,974)**	(36,660)
	Other receivables	**21,787**	(72,483)
	Refund due from Government - sales tax - net	**70,236**	30,359
		(1,273,987)	235,414
	Increase / (decrease) in current liabilities		
	Trade and other payables	**180,747**	(765,210)
	Contract liabilities	**2,705**	372
		183,452	(764,838)
	Cash flows generated from operations	**756,406**	825,874

18.	**CASH AND CASH EQUIVALENTS**		
	Cash and bank balances	**151,273**	118,394
	Running finance under markup arrangements - note 12.1	**(1,161,559)**	(1,295,363)
		(1,010,286)	(1,176,969)

19. SEGMENT INFORMATION

Based on internal management reporting structure for the period, no reportable segments were identified that were of continuing significance for decision making.

20. TRANSACTIONS WITH RELATED PARTIES

Disclosure of transactions between the Company and related parties:

The related parties include associated companies, staff retirement funds, directors, key management personnel and close family members of directors and key management personnel. The Company in the normal course of business carries out transactions with various related parties. The Company enters into transactions with related parties on the basis of mutually agreed terms. Significant transactions with related parties are as follows:

Nature of relationship		Nature of transactions	September 30 2025	September 30 2024
			(Rupees in '000)	
Parent company	-	Corporate service charges	**24,200**	15,660
	-	Rent income	**5,459**	4,859
	-	Income from provision of amenities	**3,810**	3,761
Subsidiaries				
	-	Revenue	**108,074**	197,544
	-	Purchase of consumables	**313,482**	321,761
	-	Advance against financial assistance	**249,150**	98,992
	-	Reimbursement of expenses	**19,504**	6,284
	-	Rent income	**1,240**	3,691
	-	Income from Provision of Amenities	**804**	685
	-	Others	**-**	36
Associated companies				
	-	Revenue	**6,502,514**	5,171,236
	-	Salaries and wages	**3,554**	4,586
	-	Purchases	**3,021**	1,486
	-	Carriage and duties	**11,091**	14,102
	-	Discounts claimed	**935**	67,069
	-	Rent expense	**21,230**	20,312
	-	Rent income	**13,880**	11,120
	-	Income from Provision of Amenities	**38,100**	35,569
	-	Stock claims	**10**	35,837
	-	Advance against stock claims	**21,000**	-
	-	Internet services	**11,933**	1,080
	-	Donations	**5,000**	13,390
	-	Incentives to field force staff	**-**	6,709
	-	Repair & maintenance	**153**	590
	-	Merchandise expense	**-**	1,998
	-	Others	**-**	4,938
Staff retirement benefits				
	-	Contributions to Provident Fund	**67,923**	58,299
	-	Benefits paid	**14,283**	8,562
Key management employees compensation	-	Salaries and other employee benefits	**70,510**	64,707
	-	Contributions to Provident Fund	**9,210**	6,648

20.1 The status of outstanding balances with related parties as at September 30, 2025 is included in the respective notes to the financial statements.

21. CORRESPONDING FIGURES

Corresponding figures have been reclassified and re-arranged in these financial statements, wherever necessary, to facilitate comparison and to confirm with presentation in the current period, having insignificant impact.

22. DATE OF AUTHORISATION FOR ISSUE

These unconsolidated condensed interim financial statements were approved and authorised for issue by the Board of Directors of the Company on October 24, 2025.

Chief Executive	Director	Chief Financial Officer

Consolidated Financial Statements

Directors' Report to the Members

We are pleased to present the consolidated interim financial information of the group for the three months ended September 30, 2025. These financial statements have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 – 'Interim Financial Reporting'. The directors' report is prepared in accordance with section 227 of the Companies Act, 2017 and Chapter XII of the Listed Companies (Code of Corporate Governance) Regulations, 2019.

Financial highlights

The group reported revenue of Rs. 9.70 billion, reflecting a 27% increase compared to the same period last year. The significant growth in sales was underpinned by enhanced operational efficiencies, particularly through optimization of supply chain processes and effective allocation of financial resources. The gross profit margin improved to 54.1%, marking a 8.6 percentage point increase year-on-year. This improvement was primarily driven by strategic price adjustments and a favorable shift in the product mix.

Finance costs declined substantially to Rs. 288 million, down from Rs. 755 million in the corresponding period last year. This reduction was largely attributable to lower interest rates and the settlement of long-term borrowings following the divestment of SPL.

As a result, the group recorded a profit after tax of Rs. 914 million, compared to Rs. 429 million in the corresponding quarter of the previous year.

Below is a summary of the financial results for the three months ended September 30, 2025:

	Quarter ended	
	September 30, 2025	**September 30, 2024**
	(Rupees in thousand)	
Revenue from contracts with customers	9,697,271	7,624,184
Cost of sales	(4,452,970)	(4,159,779)
Gross Profit	**5,244,301**	**3,464,405**
Distribution costs	(2,843,382)	(1,809,671)
Administrative expenses	(492,208)	(397,676)
Other expenses	(124,942)	(38,118)
Other income	39,396	39,826
Profit from operations	**1,823,165**	**1,258,766**
Finance cost	(288,407)	(755,226)
Profit before levies and income tax	**1,534,758**	**503,540**
Levies – minimum tax and final tax	(20,045)	(20,777)
Profit before income tax	**1,514,713**	**482,763**
Taxation	(600,561)	(195,202)
Profit from continuing operations	**914,152**	**287,561**
Profit from discontinued operations – net of tax	-	140,972
Profit for the period	**914,152**	**428,533**

EARNINGS PER SHARE

Basic earnings per share after taxation for the period is Rs. 1.77 (September 2024: Rs. 0.80). There is no dilution effect on the basic earnings per share of the Group, as the Group had no convertible dilutive potential ordinary shares outstanding as at September 30, 2025.

FUTURE OUTLOOK

Searle group remains focused on expanding its market presence and sustaining organic growth while continuing to improve lives. Despite ongoing macroeconomic and geopolitical challenges, the Group is confident in its ability to navigate these with resilience and deliver consistent performance.

Recent developments, including the deregulation of non-essential drug prices, lower interest rates, and a stable exchange rate have improved business predictability and created a favorable environment for growth. The recent approval of Denosumab injections by the Drug Regulatory Authority of Pakistan marks another milestone in Searle group's biosimilar journey, strengthening its leadership in biotechnology and access to affordable advanced therapies.

The Group continues to build momentum in exports, particularly across GCC and CIS markets, supported by new manufacturing approvals from regional health authorities. At the same time, Searle group is accelerating its digital transformation and sustainability initiatives to enhance operational efficiency and align with global standards.

We thank our shareholders for their continued trust and support. Searle group remains committed to disciplined execution, innovation, and creating enduring value for all stakeholders.

For and on behalf of the Board

Tahir Ahmed
Chief Executive Officer

Zubair Palwala
Director

Karachi: October 24, 2025

فی حصص آمدنی

اس مدت کے لیے ٹیکس کے بعد فی شیئر بنیادی آمدنی 1.77 روپے ہے (30 ستمبر 2024 : (0.80) روپے)۔ گروپ کی فی حصص بنیادی آمدنی پر کسی قسم کی کمی کا اثر نہیں ہوا، کیونکہ 30 ستمبر 2025 تک گروپ کے پاس کوئی قابل تبدیل ممکنہ منفی اثر ڈالنے والے عام حصص موجود نہیں تھے۔

مستقبل کا جائزہ

سرل (Searle) گروپ کی توجہ سماجی، اقتصادی، سیاسی، اور ماحولیاتی چیلنجوں کو نبرد آزما ہوتے ہوئے، نامیاتی طور پر اور اسٹریٹجک حصول کے ذریعے ترقی پر مرکوز ہے۔ ہمارا فعال نقطہ نظر اور بروقت فیصلہ سازی کا عزم ہمیں بیرونی غیر یقینی صورتحال جیسے کہ شرح مبادلہ کے اتار چڑھاو، افراط زر کے دباؤ اور بڑھتی ہوئی عالمی قیمتوں سے نمٹنے کے لیے اچھی پوزیشن میں رکھتا ہے۔

ADALIMUMAB ، پاکستان کی پہلی مقامی طور پر تیار کی جانے والی بایوسیملر دوا کی منظوری کے ساتھ ، ہم اپنی بائیو ٹیکنالوجی پیشکشوں کو مضبوط کرنے کے لیے تیار ہیں۔ مزید برآں، غیر ضروری ادویات کی قیمتوں کی حالیہ ڈی ریگولیشن اور گرتی ہوئی سود کی شرح ہمارے کاروبار کے منصوبوں میں مدد کرتے ہوئے منافع میں اضافہ کرے گی۔

ہم اہم بین الاقوامی منڈیوں میں برآمدی محصولات میں اضافہ کرنے کے منصوبوں کے ساتھ اپنے پروڈکٹ پورٹ فولیو کو متنوع بنانے، علاج کے نئے شعبوں کی تلاش، اور جغرافیائی طور پر توسیع کرنا جاری رکھے ہوئے ہیں۔ سرل (Searle) گروپ جدت اور باہمی تعاون کے ذریعے ہمارے اسٹیک ہولڈرز کے لیے طویل مدتی، پائیدار ترقی اور قدر پیدا کرنے کے لیے اچھی پوزیشن میں ہے۔

بورڈ کے لیے اور اس کی جانب سے

طاہر احمد
چیف ایگزیکٹو آفیسر

زبیر رزاق پال والا
ڈائریکٹر

کراچی: 24 اکتوبر 2025

ڈائریکٹرز رپورٹ برائے حصص یافتگان

ہمیں خوشی ہے کہ ہم گروپ کی 30 ستمبر 2025 کو ختم ہونے والی سہ ماہی کے غیر متفقہ شدہ عبوری مالیاتی گوشوارے پیش کر رہے ہیں۔ یہ مالیاتی گوشوارے بین الاقوامی اکاؤنٹنگ اسٹینڈرڈ "34 (IAS)–عبوری مالیاتی رپورٹنگ" کے تقاضوں کے مطابق تیار کیے گئے ہیں۔ ڈائریکٹرز کی یہ رپورٹ کمپنیز ایکٹ 2017 کی دفعہ 227 اور لسٹڈ کمپنیز (کارپوریٹ گورننس کے ضابطہ اخلاق) ریگولیشنز 2019 کے باب XII کے تحت تیار کی گئی ہے۔

مالی جھلکیاں

گروپ نے 9.70 ارب روپے کی آمدنی رپورٹ کی، جو گزشتہ سال کے اسی عرصے کے مقابلے میں 27% اضافہ ظاہر کرتا ہے۔ فروخت میں نمایاں اضافہ بہتر عملی کارکردگی بالخصوص سپلائی چین کے عمل کو بہتر بنانے اور مالی وسائل کے مؤثر استعمال، کے باعث ہوا ہے
۔ مجموعی منافع کا مارجن 54.1% تک بہتر ہوا، جو سال بہ سال 8.6 فیصد پوائنٹس کا اضافہ ظاہر کرتا ہے۔ یہ بہتری بنیادی طور پر اسٹریٹیجک قیمتوں میں ایڈجسٹمنٹ اور مصنوعات کے مجموعے (Product Mix) میں سازگار تبدیلی کے نتیجے میں ہوئی۔

مالیاتی اخراجات نمایاں طور پر کم ہو کر 288 ملین روپے رہ گئے، جو گزشتہ سال کے اسی عرصے میں 755 ملین روپے تھے۔ یہ کمی بنیادی طور پر کم شرحِ سود اور ایس پی ایل (SPL) کے اثاثوں کی فروخت کے بعد طویل مدتی قرضوں کی ادائیگی کی وجہ سے ہوئی۔

نتیجتاً، گروپ نے بعد از ٹیکس 914 ملین روپے کا منافع ریکارڈ کیا، جو گزشتہ سال کی اسی سہ ماہی میں 429 ملین روپے تھا۔

ذیل میں 30 ستمبر 2025 کو ختم ہونے والے تین ماہ کے مالیاتی نتائج کا خلاصہ پیش کیا جا رہا ہے:

	اختتام پذیر سہ ماہی	
	30 ستمبر 2025	30 ستمبر 2024
	(پاکستانی روپے ہزاروں میں)	
گاہکوں کے ساتھ معاہدوں سے حاصل ہونے والی آمدنی	9,697,271	7,624,184
فروخت کی لاگت	(4,452,970)	(4,159,779)
مجموعی منافع	**5,244,301**	**3,464,405**
ترسیل کے اخراجات	(2,843,382)	(1,809,671)
انتظامی اخراجات	(492,208)	(397,676)
دیگر اخراجات	(124,942)	(38,118)
دیگر آمدنی	39,396	39,826
آپریشنز سے منافع/نقصان	**1,823,165**	**1,258,766**
مالیاتی لاگت	(288,407)	(755,226)
لیویز اور انکم ٹیکس سے قبل منافع	**1,534,758**	**503,540**
لیویز - کم از کم ٹیکس اور حتمی ٹیکس	(20,045)	(20,777)
منافع قبل از ٹیکس	**1,514,713**	**482,763**
انکم ٹیکس کے اخراجات	(600,561)	(195,202)
سال کے دوران جاری کاروباری سرگرمیوں سے منافع	**914,152**	**287,561**
منقطع کاروباری سرگرمیوں سے ہونے والا منافع بعد از ٹیکس	-	140,972
منافع بعد از ٹیکس	**914,152**	**428,533**

CONSOLIDATED CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION

As at September 30, 2025

	Note	(Un-audited) September 30, 2025	(Audited) June 30, 2025
		(Rupees in '000)	
ASSETS			
Non-current assets			
Property, plant and equipment	7	**11,053,683**	11,149,935
Right-of-use asset		**41,275**	43,830
Investment properties		**6,252,725**	6,277,433
Intangibles		**4,001,908**	4,006,006
Long-term loans and advances		**46**	61
Long-term deposits		**10,824**	12,744
Deferred tax asset		**1,644,814**	1,616,811
		23,005,275	23,106,820
Current assets			
Inventories		**5,157,288**	5,253,512
Trade Receivables	8	**13,122,371**	11,600,590
Loans and advances		**1,118,349**	746,726
Trade deposits and short-term prepayments		**404,234**	319,216
Other receivables	9	**5,044,173**	5,029,809
Short-term investment at amortised cost		**-**	100,000
Taxation - payments less provision		**1,566,010**	2,059,124
Tax refunds due from government - Sales tax		**212,387**	317,038
Cash and bank balances		**277,948**	398,751
		26,902,760	25,824,766
Total assets		**49,908,035**	48,931,586
EQUITY AND LIABILITIES			
EQUITY			
Share capital		**5,114,945**	5,114,945
Share premium		**9,085,133**	9,085,133
Unappropriated profit		**12,394,467**	11,430,588
General reserve		**280,251**	280,251
Revaluation surplus on property, plant and equipment		**6,117,383**	6,178,180
Attributable to owners of			
The Searle Company Limited - Holding Company		**32,992,179**	32,089,097
Non-controlling interests		**817,757**	803,687
		33,809,936	32,892,784
LIABILITIES			
Non-current liabilities			
Long-term borrowings	10	**42,791**	46,067
Employee benefit obligations		**57,788**	58,380
Long term lease liability		**54,789**	57,514
		155,368	161,961
Current liabilities			
Trade and other payables	11	**8,010,891**	7,695,075
Short-term borrowings	12	**7,616,987**	7,857,916
Contract liabilities		**62,717**	71,577
Unpaid dividend		**196,362**	196,363
Unclaimed dividend		**43,748**	43,884
Current portion of long-term lease liability		**12,026**	12,026
		15,942,731	15,876,841
Total liabilities		**16,098,099**	16,038,802
Contingencies and commitments	13		
Total equity and liabilities		**49,908,035**	48,931,586

The annexed notes from 1 to 22 form an integral part of these consolidated condensed interim financial statements

Chief Executive | Director | Chief Financial Officer

CONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the period ended September 30, 2025 - Unaudited

	Note	Quarter Ended September 30, 2025	Quarter Ended September 30, 2024
		(Rupees in '000)	
Revenue from contract with customers	14	**9,697,271**	7,624,184
Cost of sales		**(4,452,970)**	(4,159,779)
Gross profit		**5,244,301**	3,464,405
Distribution costs		**(2,843,382)**	(1,809,671)
Administrative expenses		**(492,208)**	(397,676)
Other operating expenses		**(124,942)**	(38,118)
Other income	15	**39,396**	39,826
Profit from operations		**1,823,165**	1,258,766
Finance cost		**(288,407)**	(755,226)
Profit before levies and income tax		**1,534,758**	503,540
Levies - minimum tax and final tax		**(20,045)**	(20,777)
Profit before income tax		**1,514,713**	482,763
Income tax expense		**(600,561)**	(195,202)
Profit from continuing operations		**914,152**	287,561
Discontinued operations:			
Profit from discontinued operations – net of tax		**-**	140,972
Profit for the period		**914,152**	428,533
Profit is attributable to:			
Owners of the Parent Company - continuing operations		**903,082**	280,334
Owners of the Parent Company - discontinued operations		**-**	127,735
		903,082	408,069
Non-controlling interests - continuing operations		**11,070**	7,227
Non-controlling interests - discontinued operations		**-**	13,237
		11,070	20,464
Basic & diluted earnings per share			
From continuing operations		**1.77**	0.55
From discontinued operations		**-**	0.25
	16	**1.77**	0.80

The annexed notes from 1 to 22 form an integral part of these consolidated condensed interim financial statements

Chief Executive

Director

Chief Financial Officer

CONSOLIDATED CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY

For the period ended September 30, 2025 - Unaudited

		Capital reserves		Revenue reserves				
	Share capital	Share premium account	Reval-uation surplus on Property, plant & equip-ment	General reserve	Unap-pro-priat-ed profits	Sub-Total reserves	Non-Con-trolling interest	Total
	--(Rupees in '000)							
Balance as at July 01, 2024	5,114,945	9,085,133	6,023,513	280,251	12,027,381	27,416,278	1,913,774	34,444,997
Total comprehensive income for the period								
- Profit after tax	-	-	-	-	408,069	408,069	20,464	428,533
Transfer of incremental depreciation - net of deferred tax	-	-	(124,152)	-	124,152	-	-	-
Balance as at September 30, 2024	5,114,945	9,085,133	5,899,361	280,251	12,559,602	27,824,347	1,934,238	34,873,530
Balance as at July 01, 2025	**5,114,945**	**9,085,133**	**6,178,180**	**280,251**	**11,430,588**	**26,974,152**	**803,687**	**32,892,784**
Total comprehensive income for the period								
- Profit after tax	**-**	**-**	**-**	**-**	**903,082**	**903,082**	**11,070**	**914,152**
Transfer of incremental depreciation - net of deferred tax	**-**	**-**	**(60,797)**	**-**	**60,797**	**-**	**-**	**-**
Contribution from non controlling interest as a non-redeemable convertible loan	**-**	**-**	**-**	**-**	**-**	**-**	**3,000**	**3,000**
Balance as at September 30, 2025	**5,114,945**	**9,085,133**	**6,177,383**	**280,251**	**12,394,467**	**27,877,234**	**817,757**	**33,809,936**

The annexed notes from 1 to 22 form an integral part of these consolidated condensed interim financial statements

Chief Executive

Director

Chief Financial Officer

CONSOLIDATED CONDENSED INTERIM STATEMENT OF CASH FLOWS
For the period ended September 30, 2025 - Unaudited

	Note	**September 30, 2025**	September 30, 2024
		(Rupees in '000)	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	17	**667,731**	102,980
Employee benefit obligations paid		**(1,942)**	(5,838)
Finance cost paid		**(285,878)**	(635,487)
Income tax paid		**(155,495)**	(114,834)
(Increase) / decrease in long-term deposits		**1,920**	-
Lease rentals paid		**(7,409)**	(9,502)
Decrease / (increase) in long-term loans and advances		**15**	(922)
Net cash generated from operating activities		**218,942**	(663,603)
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		**(97,994)**	(86,680)
Sale proceeds on disposal of property, plant and equipment		**45**	-
Additions to investment properties		**(454)**	(5,060)
Net cash used in investing activities		**(98,403)**	(91,740)
CASH FLOWS FROM FINANCING ACTIVITIES			
Dividend paid		**(137)**	(355)
Non - redeemable convertible loan		**3,000**	-
(Repayment) / Proceeds of borrowings		**(3,276)**	257,350
Repayment of short-term financing		**(300,000)**	
(Repayment)/proceeds from running musharaka		**192,718**	-
Net cash generated from / (used in) financing activities		**(107,695)**	256,995
Net increase in cash and cash equivalents		**12,844**	(498,348)
Cash and cash equivalents at beginning of the period		**(896,455)**	(2,141,539)
Cash and cash equivalents at end of the period	18	**(883,611)**	(2,639,887)

The annexed notes from 1 to 22 form an integral part of these consolidated condensed interim financial statements

Chief Executive

Director

Chief Financial Officer

1. LEGAL STATUS AND OPERATIONS

1.1 The Searle Company Limited (the Company) was incorporated in Pakistan as a private limited company in October 1965. In November 1993, the Company was converted into a public limited company under the repealed Companies Ordinance, 1984 (now the Companies Act, 2017). Its shares are quoted on the Pakistan Stock Exchange Limited (PSX). The Company is principally engaged in the manufacture of pharmaceutical and other consumer products.

International Brands (Private) Limited is the Parent Company, which holds 50.25% (June 2025: 50.25%) shareholding in the Company.

Following are the subsidiary companies:

	Principal place of business	Percentage of effective holding	
		September 30, 2025 (Unaudited)	June 30, 2025 (Audited)
Listed Company			
- IBL HealthCare Limited	Pakistan	**74.19%**	74.19%
Unlisted Companies			
- Searle Pharmaceuticals (Private) Limited	Pakistan	**100.00%**	100.00%
- Searle Laboratories (Private) Limited	Pakistan	**100.00%**	100.00%
- Searle Biosciences (Private) Limited	Pakistan	**100.00%**	100.00%
- IBL Future Technologies (Private) Limited	Pakistan	**100.00%**	100.00%
- Searle IV Solutions (Private) Limited	Pakistan	**100.00%**	100.00%
- Stellar Ventures (Private) Limited	Pakistan	**100.00%**	100.00%
- IBL Frontier Markets (Private) Limited *	Pakistan	**100.00%**	100.00%
- Prime Health (Private) Limited *	Pakistan	**100.00%**	100.00%
- Mycart (Private) Limited *	Pakistan	**50.00%**	50.00%
- Nextar Pharma (Private) Limited *	Pakistan	**87.20%**	87.20%

* *Nextar Pharma (Private) Limited is the subsidiary of Searle Biosciences (Private) Limited being the indirect subsidiary of the Parent Company.*

* *MyCart (Private) Limited, IBL Frontier Markets (Private) Limited and Prime Health MyCart (Private) Limited are the subsidiaries of Stellar Ventures (Private) Limited being the indirect subsidiary of the Parent Company.*

Notes to the Consolidated Condensed Interim Financial Statements
For the period ended September 30, 2025 - Unaudited

2 BASIS OF PREPARATION

2.1 Statement of compliance

2.1.1 These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and

- Provisions of and directives issued under the Companies Act, 2017.

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

2.1.2 These consolidated condensed interim financial statements does not include all the information required for full financial statements and should be read in conjunction with the audited annual Consolidated financial statements of the Company as at and for the year ended June 30, 2025.

2.1.3 The comparative consolidated condensed interim statement of financial position presented in these unconsolidated condensed interim financial statements have been extracted from the audited annual unconsolidated financial statements of the Company for the year ended June 30, 2025, whereas the comparative unconsolidated condensed interim statement of profit or loss and other comprehensive income, unconsolidated condensed interim statement of cash flows and unconsolidated condensed interim statement of changes in equity are extracted from the un-audited unconsolidated condensed interim financial statements for the period ended September 30, 2024.

2.2 Basis of measurement

These condensed interim Consolidated financial statements have been prepared under the historical cost convention except as stated otherwise and should be read in conjunction with the audited annual Consolidated financial statements of the Company for the year ended June 30, 2025.

2.3 Functional and presentation currency

These condensed interim Consolidated financial statements are presented in Pakistani Rupees which is also the Company's functional currency. All financial information presented in Pakistani Rupees has been rounded off to the nearest thousand Rupee except where stated otherwise.

3. MATERIAL ACCOUNTING POLICY INFORMATION

3.1 The accounting policies and methods of computation adopted in the preparation of these consolidated condensed interim financial statements are the same as those applied in the preparation of the audited annual unconsolidated financial statements of the Company as at and for the year ended June 30, 2025.

3.2 Changes in accounting standards, interpretations and pronouncements

a) Standards and amendments to approved accounting standards that are effective

There are certain amendments and interpretations to the accounting and reporting standards which are mandatory for the Group's annual accounting period which began on July 1, 2025. However, these do not have any significant impact on the Group's financial reporting.

b) Standards and amendments to approved accounting standards that are not yet effective

There are certain standards, amendments and interpretations to the accounting and reporting standards that will be mandatory for the Group's annual accounting periods beginning on or after July 1, 2026. However, these will not have any impact on the Group's financial reporting and, therefore, have not been disclosed in these consolidated condensed interim financial statements.

4. FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES

The carrying values of all financial assets and liabilities reflected in these unconsolidated condensed interim financial statements approximate to their fair value.

5. SIGNIFICANT ACCOUNTING INFORMATION AND POLICIES

The accounting policies adopted in the preparation of these consolidated condensed interim financial statements are the same as those applied in the preparation of the annual financial statements of the Group for the year ended June 30, 2025.

6. ACCOUNTING ESTIMATES, JUDGEMENTS AND FINANCIAL RISK MANAGEMENT

The preparation of these consolidated condensed interim financial statements in conformity with approved accounting and reporting standards requires management to make estimates, assumptions and use judgements that affect the application of policies and reported amounts of assets and liabilities and income and expenses. Estimates, assumptions and judgements are continually evaluated and based on historical experience and other factors, including reasonable expectations of future events. Revisions to accounting estimates are recognised prospectively commencing from the period of revision.

Judgements and estimates made by the management in the preparation of this consolidated condensed interim financial information are the same as those that were applied to the annual audited consolidated financial statements as at and for the year ended June 30, 2025.

The Group's financial risk management objectives and policies are consistent with those disclosed in the annual audited consolidated financial statements as at and for the year ended June 30, 2025.

		(Unaudited) September 30, 2025	(Audited) June 30, 2025
		(Rupees in '000)	
7.	**PROPERTY, PLANT AND EQUIPMENT**		
	Operating assets - note 7.1	**10,647,032**	10,815,552
	Capital work-in-progress - at cost	**406,651**	334,383
		11,053,683	11,149,935
7.1	**Additions - operating fixed assets (at cost)**		
	Building on leasehold land	**2,896**	8,087
	Plant and machinery	**2,605**	7,803
	Office equipment	**19,605**	19,324
	Furniture and fittings	**623**	-
		25,729	35,214
8	**TRADE RECEIVABLES**		
	Considered good		
	- Export receivables, secured	**928,152**	844,040
	- Due from related parties, unsecured	**9,898,995**	8,702,668
	- Others, unsecured	**2,520,848**	2,279,506
		13,347,995	11,826,214
	Less: Provision for doubtful receivables	**(225,624)**	(225,624)
		13,122,371	11,600,590

		(Unaudited) September 30, 2025	(Audited) June 30, 2025
9	**OTHER RECEIVABLES**	(Rupees in '000)	
	Receivables from related parties		
	Due from Ultimate Parent Company and associated companies:		
	- International Brands (Private) Limited	**213,219**	295,971
	- IBL Operations (Private) Limited	**162,848**	160,125
	- Universal Ventures (Private) Limited	**200,644**	200,044
	- Mywater (Private) Limited	**-**	3,584
	- IBL Unisys (Private) Limited	**-**	1,892
		576,711	661,616
	Due from other related party:		
	- United Retail (SMC- Private) Limited	**102,389**	80,020
	- Universal Retail (SMC- Private) Limited	**202,314**	182,684
		304,703	262,704
	Surplus arising under retirement benefit fund	**5,250**	5,250
	Receivables from other than related parties		
	Noventa Pharma (Private) Limited against:		
	Sale of subsidiary	**3,400,917**	3,550,917
	Others, considered good	**756,592**	549,322
		5,044,173	5,029,809

10.	**LONG-TERM BORROWINGS**		
	Islamic		
	Diminishing musharika	**57,094**	60,370
	Less: Current portion	**(14,303)**	(14,303)
		42,791	46,067

10.1 The Parent Company obtained a musharaka facility from Habib Bank Limited (Musharaka Agent) for a period of 7 years with a repayment grace period of two years. The Parent Company is required to repay the amount of the loan in quarterly installments, starting from September 2022. This facility carries a mark-up of three months KIBOR plus 1.35%. The Parent Company has repaid the entire loan on January 30, 2025 to meet the requirement of Share Purchase Agreement (refer note 7.1) along with an early payment fee of Rs. 49.43 million.

11. TRADE AND OTHER PAYABLES

	(Unaudited) September 30, 2025	(Audited) June 30, 2025
	(Rupees in '000)	
Creditors	**2,093,402**	2,787,911
Salaries and benefits payable	**-**	4,462
Bills payable in foreign currency	**1,195,854**	1,414,453
Royalty payable	**59,187**	59,187
Accrued liabilities	**2,866,193**	1,718,433
Payable to provident fund	**35,523**	165,274
Taxes deducted at source and payable to statutory authorities	**1,062,290**	947,309
Accrued markup	**228,895**	231,050
Workers' Profit Participation Fund	**126,994**	51,089
Workers' Welfare Fund	**101,189**	72,346
Other liabilities	**241,364**	243,561
	8,010,891	7,695,075

12. SHORT-TERM BORROWINGS

	(Unaudited) September 30, 2025	(Audited) June 30, 2025
	(Rupees in '000)	
Secured borrowings		
Conventional:		
Running finance under mark-up arrangements - note 12.1	**1,161,559**	1,295,206
Short-term finance facility	**-**	300,000
	1,161,559	1,595,206
Islamic:		
Running musharaka - note 12.1 to 12.1.1	**6,429,714**	6,236,996
Current portion of long term borrowings - note 21	**14,303**	14,303
Unsecured borrowings		
IBL Holding (Private) Limited	**11,411**	11,411
	7,616,987	7,857,916

12.1 The Parent Company has entered into running finance under mark-up arrangements from various banks amounting to Rs. 7,650 million (June 30, 2025: Rs. 7,650 million) which include financing facilities obtained under Islamic mode amounting to Rs. 6,350 million (June 30, 2025: Rs. 6,350 million). The arrangements are secured jointly by registered mortgage of Rs. 1,937.5 million (June 30, 2025: Rs. 1,937.5 million) of immovable property together with a joint pari passu charge on all current assets of the Company to the extent of Rs. 11,095.83 million (June 30, 2025: Rs. 11,095.83 million).

12.1.1 The Parent Company's rates of mark-up ranged between 15.86% to 21.83% (June 30, 2025: 22.96% to 24.66%) per annum.

13. CONTINGENCIES AND COMMITMENTS

13.1 Contingencies

There has been no significant change in the status of contingencies as reported in note 29 of annual audited consolidated financial statements of the Group for the year ended June 30, 2025.

13.2 Commitments

13.2.1 The facility for opening letters of credit and guarantees of the Parent Company as at September 30, 2025 amounted to Rs. 2,982 million (June 30, 2025: Rs. 3,265 million) of which the amount remaining unutilised as at year end amounted to Rs. 1,981 million (June 30, 2025: Rs. 1,180 million).

13.2.2 The facility for opening Letters of Credit of IBL HealthCare Limited as at September 30, 2025 amounted to Rs. 900 million (June 2025: Rs. 900 million) and Rs. 40 million (June 2025: Rs. 20 million) of which the amount remained unutilized as at balance sheet date was Rs. 412.307 million (June 2025: Rs. 246.27 million).

14. REVENUE FROM CONTRACT WITH CUSTOMERS

	September 30, 2025	September 30, 2024
	(Rupees in '000)	
Gross sales		
Local sales	**10,017,236**	8,571,563
Export sales	**851,775**	787,418
	10,869,011	9,358,981
Toll manufacturing	**1,245**	-
	10,870,256	9,358,981
Sales tax	**(243,416)**	(216,908)
	10,626,840	9,142,073
Less:		
Discounts, rebates and allowances	**(564,697)**	(700,348)
Sales returns	**(364,872)**	(817,541)
	(929,569)	(1,517,889)
	9,697,271	7,624,184

		September 30, 2025	September 30, 2024
15.	**OTHER INCOME**	(Rupees in '000)	
	Income from financial assets		
	Interest income on Term Finance Certificate	-	5,505
	Income from non - financial assets		
	Rental income from investment properties	25,681	22,490
	Gain on disposal of property, plant and equipment	45	-
	Scrap sales	9,354	8,544
	Others	2,358	3,287
		37,438	34,321
		39,396	39,826

		September 30, 2025	September 30, 2024
16.	**BASIC AND DILUTED EARNINGS PER SHARE**	(Rupees in '000)	
			(Re-stated)
	Profit for the period	903,082	408,069
	Weighted average number of outstanding shares at the end of the period (in thousand)	511,494	511,494
	Basic and diluted earnings per share (Rupees)	1.77	0.80

		September 30, 2025	September 30, 2024
		(Rupees in '000)	
17.	**CASH GENERATED FROM OPERATIONS**		
	Profit before income tax	**1,534,758**	702,317
	Add / (less): Adjustments for non-cash charges and other items		
	Depreciation on property, plant and equipment	**193,984**	231,737
	Depreciation on investment property	**25,162**	28,661
	Depreciation on right-of-use-asset	**2,555**	4,830
	Gain on disposal of property, plant and equipment	**217**	-
	Amortisation	**4,098**	5,504
	Provision for retirement benefits obligation	**1,350**	2,506
	Interest income	**-**	5,505
	Finance cost	**283,723**	863,145
	Interest on lease liability	**4,684**	6,573
	Amortisation of transaction cost	**-**	4,212
	Provision for doubtful receivable	**-**	10,100
	Profit before working capital changes	**2,050,531**	1,865,090
	Effect on cash flow due to working capital changes		
	(Increase) / decrease in current assets		
	Inventories	**96,224**	434,774
	Trade receivables	**(1,521,781)**	(598,810)
	Loans and advances	**(371,623)**	(24,096)
	Trade deposits and short-term prepayments	**(85,018)**	(90,100)
	Short-term investment at amortised cost	**100,000**	-
	Tax refunds due from government - Sales tax	**104,651**	35,818
	Other receivables	**(14,364)**	(379,527)
		(1,691,911)	(621,941)
	Increase / (decrease) in current liabilities		
	Trade and other payables	**317,971**	(1,133,828)
	Contract liabilities	**(8,860)**	(6,341)
	Cash generated from operations	**667,731**	102,980
18.	**CASH AND CASH EQUIVALENTS**		
	Cash and bank balances	**277,948**	305,190
	Short term running finances - note 12	**(1,161,559)**	(2,945,077)
		(883,611)	(2,639,887)

19. SEGMENT INFORMATION

Based on internal management reporting structure for the period, no reportable segments were identified that were of continuing significance for decision making.

20. TRANSACTIONS WITH RELATED PARTIES

Disclosure of transactions between the Group and related parties

The related parties include the ultimate parent company, associated companies or undertakings, staff retirement funds, directors of the Group, key management personnel and key management personnel. The Group in the normal course of business carries out transactions with various related parties. The Group enters into transactions with related parties on the basis of mutually agreed terms. Significant transactions with related parties are as follows:

Nature of relationship		Nature of transactions	**September 30, 2025**	September 30, 2024
			(Rupees in '000)	
Ultimate parent company	-	Corporate service charges	**24,200**	15,660
	-	Rent income	**5,459**	4,859
	-	Income from provision of amenities	**3,810**	3,761
Associated companies	-	Revenue	**6,502,514**	5,171,236
	-	Salaries and wages	**3,554**	4,586
	-	Purchases	**3,021**	1,486
	-	Carriage and duties	**11,091**	14,102
	-	Discounts claimed	**935**	67,069
	-	Rent expense	**21,230**	20,312
	-	Rent income	**13,880**	11,120
	-	Stock claims	**10**	35,837
	-	Internet services	**5,046**	1,080
	-	Income from provision of amenities	**38,100**	35,569
	-	Donations	**5,000**	13,390
	-	Incentives to field force staff	**-**	6,709
	-	Repair and maintenance	**153**	590
	-	Merchandise expense	**-**	1,998
	-	Others	**-**	4,938
Key management employees compensation	-	Salaries and other employee benefits	**67,923**	58,299
	-	Contributions to Provident Fund	**14,283**	8,562

20.1 The status of outstanding balances with related parties as at September 30, 2025, are included in the respective notes to the consolidated financial statements.

21. CORRESPONDING FIGURES

Corresponding figures have been reclassified and re-arranged in these consolidated financial statements, wherever necessary, to facilitate comparison and to confirm with presentation in the current period, having insignificant impact.

22. DATE OF AUTHORISATION FOR ISSUE

This consolidated condensed interim financial information was approved and authorised for issue by the Board of Directors of the Parent Company on October 24, 2025.

Chief Executive	Director	Chief Financial Officer

THE SEARLE COMPANY LIMITED
2nd Floor, One IBL Centre, Plot# 1, Block 7 & 8,
Dehli Mercantile Muslim Cooperative Housing Society
(DMCHS) Tipu Sultan Road, Off. Shahrah-e-Faisal, Karachi
URL: www.searlecompany.com